Effect Of The Combination Of Automated Peripheral Mechanical Stimulation And Physical Exercise On Aerobic Functional Capacity And Cardiac Autonomic Control: A Randomized Clinical Trial Protocol.

2021 ◽  
Author(s):  
Nicolle Aileen Zelada-Astudillo ◽  
Andrea Herrera-Santelices ◽  
Fabio Augusto Barbieri ◽  
Vinicius Christianini Moreno ◽  
Antonio Roberto Zamunér

Abstract ● Background: Automated peripheral mechanical stimulation (AMPS) has been proposed as a new complementary therapy with potential for improving motor and cardiovascular abnormalities in Parkinson's disease (PD). However, AMPS long-term effects and its combination with physical exercise is unknown. Thus, this study aims to compare the effects of a program of 12 weeks of physical exercise with a 12-week intervention program combining physical exercise and AMPS on the aerobic capacity, cardiac autonomic control and gait parameters in patients with PD.● Methods: A randomized, controlled clinical trial will be conducted. Volunteers will be randomly assigned to one of the two groups studied: 1) Exercise; or 2) AMPS + Exercise. Both groups will undergo an exercise program of 24 sessions, for 12 weeks, performed twice a week. Before exercise sessions, the group AMPS+Exercise will receive a session of active AMPS, while the group Exercise will receive an AMPS sham intervention. Shapiro-wilk’s and Levene’s tests will be used to check for data normality and homogeneity, respectively. In case parametric assumptions are fulfilled, per-protocol and intention-to-treat analyses will be performed using a mixed model analysis of variance to check for Group*Time interaction. Significance level will be set at 5%. ● Discussion: Several non-pharmacological treatment modalities have been proposed for PD, focusing primarily on the reduction of motor and musculoskeletal disorders. Regular exercise and motor training have been shown to be effective in improving quality of life. However, treatment options in general remain limited given the high prevalence and adverse impact of these disorders. So, developing new strategies that can potentiate the improvement of motor disabilities and also improve non-motor symptoms in PD is relevant. It is expected that the participants from both groups will improve their quality of life, gait parameters and their cardiac autonomic control, with greater improvements being observed in the group combining active AMPS and physical exercise.Trial registration: ClinicalTrials.gov, NCT04251728, registered February 05, 2020

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Nicolle Zelada-Astudillo ◽  
Vinicius Christianini Moreno ◽  
Andrea Herrera-Santelices ◽  
Fabio Augusto Barbieri ◽  
Antonio Roberto Zamunér

Abstract Background Automated peripheral mechanical stimulation (AMPS) has been proposed as a new complementary therapy with potential for improving motor and cardiovascular abnormalities in Parkinson’s disease (PD). However, AMPS long-term effects and its combination with physical exercise are unknown. Thus, this study aims to compare the effects of a program of 12 weeks of physical exercise with a 12-week intervention program combining physical exercise and AMPS on the aerobic capacity, cardiac autonomic control, and gait parameters in patients with PD. Methods A randomized, controlled clinical trial will be conducted. Older volunteers with PD will be randomly assigned to one of the two groups studied: (1) exercise or (2) AMPS + exercise. Both groups will undergo an exercise program of 24 sessions, for 12 weeks, performed twice a week. Before exercise sessions, the group AMPS + exercise will receive a session of active AMPS, while the group exercise will receive an AMPS sham intervention. Shapiro-Wilk’s and Levene’s tests will be used to check for data normality and homogeneity, respectively. In case parametric assumptions are fulfilled, per-protocol and intention-to-treat analyses will be performed using a mixed model analysis of variance to check for group*time interaction. Significance level will be set at 5%. Discussion Several non-pharmacological treatment modalities have been proposed for PD, focusing primarily on the reduction of motor and musculoskeletal disorders. Regular exercise and motor training have been shown to be effective in improving quality of life. However, treatment options in general remain limited given the high prevalence and adverse impact of these disorders. So, developing new strategies that can potentiate the improvement of motor disabilities and also improve non-motor symptoms in PD is relevant. It is expected that the participants from both groups will improve their quality of life, gait parameters, and their cardiac autonomic control, with greater improvements being observed in the group combining active AMPS and physical exercise. Trial registration ClinicalTrials.gov NCT04251728. Registered on February 05, 2020.


2020 ◽  
Vol 40 (2) ◽  
pp. 168-174 ◽  
Author(s):  
Olívia Maria Costa Figueredo ◽  
Mariana Barbosa Câmara‐Souza ◽  
Talita Malini Carletti ◽  
Renata Cunha Matheus Rodrigues Garcia

Cephalalgia ◽  
1997 ◽  
Vol 17 (8) ◽  
pp. 867-872 ◽  
Author(s):  
NC Santanello ◽  
AB Polis ◽  
SL Hartmaier ◽  
MS Kramer ◽  
GA Block ◽  
...  

A validated migraine-specific questionnaire (24-h Migraine Quality of Life Questionnaire1: 24-h MQoLQ) was used to assess the impact of migraine and migraine therapy on health related quality of life during an acute migraine attack. Male and female migraineurs aged 18-55 years were randomized to placebo ( n = 41), rizatriptan 2.5 mg ( n = 47), 5 mg ( n = 74), or 10 mg ( n = 85) in a triple-blind, placebo-controlled clinical trial. Rizatriptan 5 mg and 10 mg were significantly more efficacious than placebo on pain relief and functional disability. After accounting, for multiple comparisons to placebo, rizatriptan 10 mg showed significantly better responses compared to placebo on three of five domains of 24-h MQoLQ (social functioning, migraine symptoms, and feelings/concerns). The O'Brien's Rank Sum Test statistic showed a statistically significant overall difference on the 24-h MQoLQ between the 10 mg rizatriptan and placebo groups ( p = 0.005) and for the overall close trend ( p 0.001).


Sign in / Sign up

Export Citation Format

Share Document